Biopharma

New study paves way for immunotherapies tailored for ch...

Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital...

AI paves the way for personalised treatments in ageing ...

A collaborative study between researchers from the Yong Loo Lin School of Medici...

Scientists design peptides to enhance drug efficacy

A team of scientists has developed a groundbreaking approach using specially des...

Microbial therapy offers new hope for vitiligo patients

A natural compound derived from gut-friendly bacteria significantly slows the pr...

Skin cancer: New treatment option successfully tested

Basal cell carcinomas, the most common form of skin cancer, occur in chronically...

Researchers identify genetic 'fingerprint' to...

Antibiotic resistance is a global public health crisis responsible for more than...

Harnessing generative AI to treat undruggable diseases

Biomedical engineers at Duke University have developed an AI-based platform that...

Cardiovascular disease medications underused globally

Secondary prevention medications for cardiovascular diseases (CVD) are underused...

Gene therapy may be "one shot stop" for rare bone disease

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) h...

AI accelerates the search for new tuberculosis drug tar...

Tuberculosis is a serious global health threat that infected more than 10 millio...

Omega-3s can slow down aging process

Many people would like to delay or even stop the aging process. Previous clinica...

AI tool helps find life-saving medicine for rare disease

After combing through 4,000 existing medications, an artificial intelligence too...

Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...

Novo outlines new late-stage study of obesity drug Cagr...

CagriSema, which underperformed expectations in its first Phase 3 test, will be ...

Cullinan CEO talks autoimmune pivot, upcoming lupus rea...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to ...

Fierce Biotech Layoff Tracker 2025: Viracta shuts down;...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Boston Scientific clocks over $1B in Farapulse revenue ...

That includes treating more than 200,000 patients with the irregular heartbeat k...

Glucotrack’s 3-year diabetes sensor implant clears init...

Glucotrack has cleared the first human clinical study of its long-term continuou...

X4 lays off 30% of staff, halts preclinical R&D to focu...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...

AstraZeneca CEO defends 'fantastic' Alexion buyout in f...

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...

LinusBio to launch autism diagnostic aid that uses a si...

LinusBio aims to help physicians rule out the likelihood of autism developing in...

BD bids farewell to its diagnostic, bioscience division...

The “New BD,” as the company describes it, will continue on as a pure-play medte...

Kura and Kyowa hail phase 2 win for leukemia drug soon ...

Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral ...

Eli Lilly's next R&D focus: Testing incretin meds in ne...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside ...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.